The downgraded H3815 contract covers over 75% of the company’s health-plan members, triggering immediate reactions from market analysts. Both Bank of America and William Blair responded to the news by downgrading the stock to neutral or market perform positions, with the latter slashing its price target by more than 60%. The sell-off saw the stock price fall from $8.71 at the close of October 8 to $6.95 at the open the following morning.

This decline follows months of investor uncertainty regarding the firm's regulatory outlook. During an earnings call on July 30, 2026, CEO John E. Kao expressed confidence in the company's position despite the volatility surrounding star ratings. However, his refusal to discuss specific rating outcomes during a September 15 conference—where he noted he did not want to "poke the bear"—now faces scrutiny. Legal representatives are currently evaluating whether previous company statements may have artificially inflated share prices prior to the October 8 disclosure.